A French population-based cohort study, The French Safety and Appropriateness of Growth Hormone treatments in Europe (SAGhE), of patients treated with recombinant GH reported an increased risk of bone cancers (n = 3 cases observed versus 0.6 expected; SMR 5.00; 95% CI, 1.01–14.63), both osteosarcoma (2 cases, statistically nonsignificant) and Ewing sarcoma (1 case, statistically significant) [49]. The gene discussed is GH1; the disease is bone cancer.